SynthesisFluids and barriers of the CNS2024
Molecular determinants for brain targeting by peptides: a meta-analysis approach with experimental validation.
Synthesis in Fluids and barriers of the CNS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Multivalent peptides for blood-brain barrier translocation, cell penetration and microRNA-21 inhibition in glioblastoma.RSC chemical biology · 2026Article
- Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration.Chemical science · 2026Article
- INBAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Recent Advances in the Non-viral Delivery of Genes to Central Nervous System Disorders.Cellular and molecular neurobiology · 2026Review
- Peptide-functionalized nanoparticles for brain-targeted therapeutics.Drug delivery and translational research · 2026Review
- Prediction of blood-brain barrier-penetrating peptides using B3BPFN.Frontiers in molecular biosciences · 2026Article
- Peptide-Based Therapeutics for Alzheimer's Disease: Medicinal Chemistry, AI-Guided Computational Design, and Blood-Brain Barrier Delivery.Drug design, development and therapy · 2026Review
- Cracking the Blood-Brain Barrier Code: Rational Nanomaterial Design for Next-Generation Neurological Therapies.Pharmaceutics · 2025Review
- PepH3-modified nanocarriers for delivery of therapeutics across the blood-brain barrier.Fluids and barriers of the CNS · 2025Article
- New Trends in Brain Shuttle Peptides.Molecular pharmaceutics · 2025Review
- Design of Natterins-based peptides improves antimicrobial and antiviral activities.Biotechnology reports (Amsterdam, Netherlands) · 2025Article
- Cell-penetrating peptides TAT and 8R functionalize P22 virus-like particles to enhance tissue distribution and retentionFrontiers in veterinary science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Blood-brain barrier (BBB) peptide-shuttles (BBBpS) are able to translocate the BBB and reach the brain. Despite the importance of brain targeting in pharmacology, BBBpS are poorly characterized. Currently, their development relies on the empiric assumption that cell-penetrating peptides (CPPs), with proven ability to traverse lipid membranes, will likewise behave as a BBBpS. The relationship between CPPs/BBBpS remains elusive and, to the best of our knowledge, has not hitherto been subject to thorough experimental scrutiny. In this work, we have identified/quantified the main physicochemical properties of BBBpS and then searched for CPPs with these properties, hence potential BBBpS. The specific features found for BBBpS are: (i) small size, (ii) none or few aromatic residues, (iii) hydrophobic, and (iv) slight cationic nature. Then, we selected the 10 scoring best in an ordinary least squares analysis, and tested them in vitro and in vivo. Overall, we identified the molecular determinants for brain targeting by peptides, devised a methodology that can be used to assist in the design of peptides with potential brain penetration from amino acid residue sequences, and found four new BBBpS within the CPP library.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.